5、Hudis C, Citron M, Berry D. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective [abstract 41] Breast Cancer Res Treat. 2005;94(Suppl 1):S20.
6、Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685
7、Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334
8、Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L: Response to neoadyuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281
9、Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Page 7 of 9Makhson A, Tjulandin S, Ludwig H, Verill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, Clark E, Galbraith S: Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009, 27:526-534.
10、Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M: Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009, 9:29-33.
11、Garber JF, Richardson A, Harris LN: Neo-adjuvant cisplatin (CDDP) in
‘triple-negative’ breast cancer (BC) [abstract 308]. Breast Cancer Res Treat 2006, 100(Suppl 1):S32
12、Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple negative breast cancer. Annals Oncol. 2008;19:1847–1852. doi: 10.1093/annonc/mdn395.
13、Chia JW, Ang P, See H. Triple-negative metastasic/recurrent breast cancer: treatment with paclitaxel/carboplatin combination chemotherapy [abstract 1086] J Clin Oncol. 2007;25(Suppl 18):53s.
14、Tan AR, Swain SM. Therapeutic strategies for triple-negative breast cancer. Cancer J.2008;14:343–351. doi: 10.1097/PPO.0b013e31818d839b.
15、Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676. doi: 10.1056/NEJMoa072113
16、Miles D, Chan A, Romieu G. Randomized, doubled-blind, placebo-controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract LBA 1011]J Clin Oncol.? 2008;26(Suppl 15):1008s.
17、Robert N, Dieras V, Glaspy J. Ribbon-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of
HER2-negative locally recurrent or metastatic breast cancer (MBC) J Clin Oncol. 2009;27(Suppl 15):Abstract 1005.
18、Baselga J, Roche H, Costa F. SOLTI 0701: a multinacional double-blind, randomized
- 6 -
phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer [abstract 45] Proceedings of the San Antonio Breast Cancer Symposium. 2009. 32nd Annual San Antonio Breast Cancer Symposium
19、Gradishar W, Kaklamani V, Prasad Sahoo T. A double-blind, randomized,
placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib in combination with paclitaxel as a first line therapy in patients with locally recurrent or metastatic breast cancer [abstract 44]Proceedings of the San Antonio Breast Cancer Symposium.? 2009. 32nd Annual San Antonio Breast Cancer Symposium
20、Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swasiland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribosa) polymerase in tumors from BRCA mutation carriers. N Engl J Med.2009;361:123–134. doi: 10.1056/NEJMoa0900212
21、Corkery B, Crown J, Clynes M, O'Donavan N. Epidermal growth factor receptor as a potential therapeutic target in triple negative breast cancer. Ann Oncol. 2009;20:862–867. doi: 10.1093/annonc/mdn710
22、Carey L, Rugo H, Marcom S. TBCRC 001: EGFR inhibition with cetuximab added to carboplatinum in metastatic TNBC (basal like) J Clin Oncol. 2008;26(suppl 15):Abstract 1009. 23、O'Shaughnessy J, Weskstein D, Vukelja S. Results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer.Breast Cancer Res Treat.? 2007;106(Suppl 1):S32.
24、Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauldea S, Marimón I, Tabernero JM, Koehler MT, Rojo F. Phase II and pharmacodynamic study of Gefitinib in patients with advanced breast cancer. J Clin Oncol. 2005;23:5323–5333. doi: 10.1200/JCO.2005.08.326
25、Barrios C, Liu M, Lee S. A phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER 2 negative advanced breast disease (SUN 1107) [abstract 46] Proceedings of the San Antonio Breast Cancer Symposium. 2009. 32nd Annual San Antonio Breast Cancer Symposium
26、Finn R, Bengala C, Ibrahim N. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA. Cancer Res. 2009;69(Suppl 2):Abstract 3118.
27、Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Michaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND. J Clin Oncol.2009;27:4536–4541. doi: 10.1200/JCO.2008.21.3033
28、STEBBINS CE, RUSSO AA,SCHNEIDER C, et al. Crystal structure of an
Hsp90-geldanamycin complex;targerting of a protein chaperone by an antirumor agent[J]. Cell, 1997, 89(2):2 39-250.
29、Caldas-Lopez E, Cerchietti L, Ahn J, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchine E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of maliganancy induces complete responses in triple negative breast cancer models. Proc Natl Acad Sci U S A.2009;106:8368–8373. doi: 10.1073/pnas.0903392106.
- 7 -
